From Ariad Loads Up With $200M Stock Deal, After Big Medical Meeting:

ariadhuge

ariadhuge—

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

From Our Editors · Special Report
Xcelerating Life Sciences Philadelphia: Special Report
Becoming the Cell & Gene Therapy Hub

Xconomy on Demand

We offer a number of ways to subscribe for free!